Retatrutide and trizepatide represent a recent class of medications that act on both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists demonstrate significant therapeutic potential in the control of type 2 diabetes. Retatrutide, a once-weekly subcutaneous injection, st